Video

What COVID-19 Vaccines Teach Us About All Tech Transfers

Source: Outsourced Pharma

Are there “lessons learned” and “best practices” from the COVID-19 vaccine efforts you can apply to tech transfers of your own projects – be they small molecule, biologics, or cell and gene therapies?

View the On-Demand version of OP-Virtual from our discussion on November 4, 2020 on what we’ve learned thus far, and how to “transfer” that knowledge to your projects.

Our panelists:

  • Bikash Chatterjee, CEO | Pharmatech Associates
  • David A. Dodd, Chairman, CEO | GeoVax
  • Marcelo Omelczuk, (former) VP, Global Pharmaceutical Technology and Launch Management | Allergan
  • Mark F. Witcher, Ph.D., (former) VP Manufacturing | Amgen & (former) SVP Operations | Covance
  • Louis Garguilo, Chief Editor | Outsourced Pharma

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)